Study of Acamprosate in Fragile x Syndrome
Double-Blind, Placebo-Controlled Proof of Concept Study in Youth With Fragile X Syndrome
Sponsor: Children's Hospital Medical Center, Cincinnati
Listed as NCT01911455, this PHASE1 trial focuses on Fragile X Syndrome and remains completed. Sponsored by Children's Hospital Medical Center, Cincinnati, it has been updated 9 times since 2013, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
9 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1
-
Mar 2021 — Jul 2024 [monthly]
Completed PHASE1
Status: Active Not Recruiting → Completed · Phase: PHASE2_PHASE3 → PHASE1
-
Jan 2021 — Mar 2021 [monthly]
Active Not Recruiting PHASE2_PHASE3
-
Apr 2020 — Jan 2021 [monthly]
Active Not Recruiting PHASE2_PHASE3
▶ Show 4 earlier versions
-
Mar 2019 — Apr 2020 [monthly]
Active Not Recruiting PHASE2_PHASE3
Status: Recruiting → Active Not Recruiting
-
Jun 2018 — Mar 2019 [monthly]
Recruiting PHASE2_PHASE3
-
Feb 2017 — Jun 2018 [monthly]
Recruiting PHASE2_PHASE3
-
Jan 2017 — Feb 2017 [monthly]
Recruiting PHASE2_PHASE3
First recorded
Aug 2013
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Children's Hospital Medical Center, Cincinnati
- Rush University Medical Center
For direct contact, visit the study record on ClinicalTrials.gov .